NEWS | MedXCell

MedXCell pipeline company CYTEA|BIO to attend the Jefferies Healthcare Conference in London (November 15-17, 2022)

Montreux, Switzerland | November 2, 2022 – CYTEA|BIO, a preclinical-stage biotechnology company focusing on allogeneic cellular immunotherapies combining non genetically modified effector cells (such as

MedXCell SA is proud to announce the arrival of Andrew Galazka and John D. McMannis as new members of the Board and Pierre J.Magistretti as new scientific advisor

Montreux, Switzerland | March 11, 2022 – MedXCell SA, a Swiss biotech company dedicated to transforming healthcare through the development and production of affordable and

MedXCell SA is pleased to announce the appointment of Dr Jean-Jacques de Dardel as a member of the Board of Directors.

Montreux, Switzerland | August 26, 2021 – MedXCell SA, a Swiss biotech company dedicated to transforming healthcare through the development and production of affordable and accessible

MedXCell SA has successfully closed a CHF 5.3 million Series A

Montreux, Switzerland | June 4, 2021 – MedXCell SA, a Swiss biotech company dedicated to transforming healthcare through the development and production of affordable and

MedXCell SA is proud to announce the arrival of Gabriel Baertschi as a new member of the Board

Montreux, Switzerland | May 17, 2021 – MedXCell SA, a Swiss biotech company dedicated to transforming healthcare through the development and production of affordable and

MedXCell SA selected to participate in the sixth edition of the pre-IPO program TechShare organized by Euronext

Montreux, Switzerland | January 21, 2021 – MedXCell SA, a Swiss biotech company dedicated to transforming healthcare through the development and production of affordable and